Ampio Pharmaceuticals, Inc. (NYSEAMERICAN:AMPE – Get Rating) CEO Michael A. Martino bought 76,890 shares of the company’s stock in a transaction on Wednesday, May 24th. The shares were purchased at an average cost of $0.29 per share, for a total transaction of $22,298.10. Following the transaction, the chief executive officer now owns 76,890 shares in the company, valued at $22,298.10. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.
Ampio Pharmaceuticals Trading Up 6.4 %
Shares of NYSEAMERICAN:AMPE traded up $0.02 during mid-day trading on Friday, reaching $0.30. The company had a trading volume of 422,326 shares, compared to its average volume of 291,843. The firm has a market cap of $4.60 million, a price-to-earnings ratio of -0.15 and a beta of 1.48. The company’s 50-day moving average price is $0.24 and its 200-day moving average price is $0.26. Ampio Pharmaceuticals, Inc. has a one year low of $0.18 and a one year high of $3.94.
Ampio Pharmaceuticals (NYSEAMERICAN:AMPE – Get Rating) last posted its quarterly earnings results on Monday, May 8th. The specialty pharmaceutical company reported ($0.26) EPS for the quarter.
Institutional Investors Weigh In On Ampio Pharmaceuticals
Analyst Ratings Changes
Separately, StockNews.com assumed coverage on shares of Ampio Pharmaceuticals in a research report on Saturday, May 20th. They set a “sell” rating on the stock.
Ampio Pharmaceuticals Company Profile
Ampio Pharmaceuticals, Inc operates as a biopharmaceutical company. The firm engages in the development of therapies to treat prevalent inflammatory conditions. Its product pipeline includes new uses for approved drugs and new molecular entities for important therapeutic areas, including metabolic disease, eye disease, kidney disease, inflammation and sexual dysfunction and CNS disease.
- Get a free copy of the StockNews.com research report on Ampio Pharmaceuticals (AMPE)
- Big Lots Becomes A Stomach Churning Value Play
- The Melt-Up In Marvell Is On; But Don’t Chase It Higher
- Is Apple a Growth Stock or a Value Stock?
- Costco’s Earnings Call Reassure Economists, Recession Cancelled
- Hot Inflation, What It Means For The Summer Rally
Receive News & Ratings for Ampio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ampio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.